P/LP variants in other CSGs (ATM, FANCM, BRIP1, MSH6, BRCA2, PMS2 and TP53) found in 2% participants could reflect a background prevalence in the population or an association with RCC that has not yet been validated. This evidence concerns the gene TP53 and renal cell carcinoma.